09/10/2025
Big news in the psychedelic space: MindMed has just dosed the first patient in a Phase 3 clinical trial using MM-120 (an L*D-based medicine) for Major Depressive Disorder.
This is history in the making — the first time L*D has reached Phase 3 trials for depression. It’s one more step toward legitimizing what many of us have already experienced: plant medicines can be powerful tools for healing when approached with intention and support.
At Ash to Ember, we’re watching these developments closely. Science is catching up with what sacred medicines have been teaching us all along.
https://ir.mindmed.co/news-events/press-releases/detail/178/mindmed-announces-first-patient-dosed-in-phase-3-emerge-study-of-mm120-in-major-depressive-disorder-mdd?fbclid=IwY2xjawMpOHxleHRuA2FlbQIxMABicmlkETFVSUN1eTMxa2o3WEo2cnpRAR6vxicfb5WL0LFSTVWLgnhzNP_jZbbNaJGrx6Y8ub4xKYZphzobGK_yV-oqpw_aem_2VspfXRy8_CG8tl8ZK8C-g
- Emerge is the first Phase 3 study of lysergide D-tartrate (L*D) in MDD; primary endpoint will measure change from baseline in…...